Intraperitoneal immunotherapy: historical perspectives and modern therapy
Intraperitoneal immunotherapy represents a novel strategy for the management of peritoneal metastases (PM). Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has remained the gold standard of treatment for patients with PM, yet despite optimal treatment, recurrence ra...
Gespeichert in:
| Veröffentlicht in: | Cancer gene therapy 2016-11, Vol.23 (11), p.373-381 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 381 |
|---|---|
| container_issue | 11 |
| container_start_page | 373 |
| container_title | Cancer gene therapy |
| container_volume | 23 |
| creator | Morano, W F Aggarwal, A Love, P Richard, S D Esquivel, J Bowne, W B |
| description | Intraperitoneal immunotherapy represents a novel strategy for the management of peritoneal metastases (PM). Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has remained the gold standard of treatment for patients with PM, yet despite optimal treatment, recurrence rates remain high and long-term survival poor. From Coley’s toxins to immune checkpoint inhibitors, the wide variety of anticancer immunotherapeutic strategies are now garnering attention for control of regional disease of the peritoneal cavity. Early studies with vaccine-based therapies, adoptive cell transfer, immune checkpoint inhibitors, and chimeric T cells with tumor-specific antigen receptors (CAR-T cells) are being performed, showing promise for control of peritoneal spread and induction of lasting anticancer immunity. In addition, catumaxomab, a trifunctional antibody, has been approved for intraperitoneal immunotherapy in Europe for the control of malignant ascites in patients with epithelial cell adhesion molecule positive cancers. We review a brief history of immunotherapy and current modalities under investigation for intraperitoneal use in the treatment of PM. |
| doi_str_mv | 10.1038/cgt.2016.49 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1846393818</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A470451260</galeid><sourcerecordid>A470451260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c616t-9f77249a1ad48d94e503d9e7c2b67370bbe7ff1469af1473cc1cac08a31936d83</originalsourceid><addsrcrecordid>eNqN0s1rFDEUAPAgil2rJ-8yIIigs-Zr8uGtFLULBS96DtlMZjdlJlmTjND_3rfsVttSigQSyPslj5c8hF4TvCSYqU9uU5cUE7Hk-glaEC5F23UYP0ULrKluicbsBL0o5QpjCEr2HJ1QqRhnnVqg1SrWbHc-h5qit2MTpmmOqW497F5_brah1JSDgwigsvOuht--NDb2zZR6n2NztC_Rs8GOxb86rqfo59cvP84v2svv31bnZ5etE0TUVg9SUq4tsT1Xvea-w6zXXjq6FpJJvF57OQyEC21hlsw54qzDyjKimegVO0XvD_fucvo1-1LNFIrz42ijT3MxRHHBNFPkfyjThFLOGNC39-hVmnOEQgwVnEgqMbhHFKTFikNu9U9t7OhNiEOCJ3b71OaMS8w7QgUGtXxAwej9FBx8xhBg_86Bd7cObOGz6rakca4hxXIXfjhAl1Mp2Q9ml8Nk87Uh2OxbxkDLmH3LGK5BvznWNK8n3_-1Nz0C4OMBFAjFjc-3in7gvj9KlMcN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1840848468</pqid></control><display><type>article</type><title>Intraperitoneal immunotherapy: historical perspectives and modern therapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Morano, W F ; Aggarwal, A ; Love, P ; Richard, S D ; Esquivel, J ; Bowne, W B</creator><creatorcontrib>Morano, W F ; Aggarwal, A ; Love, P ; Richard, S D ; Esquivel, J ; Bowne, W B</creatorcontrib><description>Intraperitoneal immunotherapy represents a novel strategy for the management of peritoneal metastases (PM). Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has remained the gold standard of treatment for patients with PM, yet despite optimal treatment, recurrence rates remain high and long-term survival poor. From Coley’s toxins to immune checkpoint inhibitors, the wide variety of anticancer immunotherapeutic strategies are now garnering attention for control of regional disease of the peritoneal cavity. Early studies with vaccine-based therapies, adoptive cell transfer, immune checkpoint inhibitors, and chimeric T cells with tumor-specific antigen receptors (CAR-T cells) are being performed, showing promise for control of peritoneal spread and induction of lasting anticancer immunity. In addition, catumaxomab, a trifunctional antibody, has been approved for intraperitoneal immunotherapy in Europe for the control of malignant ascites in patients with epithelial cell adhesion molecule positive cancers. We review a brief history of immunotherapy and current modalities under investigation for intraperitoneal use in the treatment of PM.</description><identifier>ISSN: 0929-1903</identifier><identifier>EISSN: 1476-5500</identifier><identifier>DOI: 10.1038/cgt.2016.49</identifier><identifier>PMID: 27834358</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>631/250/251 ; 631/67/1059 ; 631/67/322 ; Animals ; Antibodies, Bispecific - therapeutic use ; Antineoplastic Agents, Immunological - therapeutic use ; Ascites ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Care and treatment ; Cell adhesion molecules ; Chemotherapy ; Debulking ; Epithelial cells ; Gene Expression ; Gene Therapy ; History, 20th Century ; History, 21st Century ; Humans ; Hyperthermic intraperitoneal chemotherapy ; Immune checkpoint inhibitors ; Immunotherapy ; Immunotherapy - history ; Lymphocytes T ; Metastases ; Patients ; Peritoneal diseases ; Peritoneal Neoplasms - secondary ; Peritoneal Neoplasms - therapy ; Peritoneum ; review</subject><ispartof>Cancer gene therapy, 2016-11, Vol.23 (11), p.373-381</ispartof><rights>Nature America, Inc., part of Springer Nature. 2016</rights><rights>COPYRIGHT 2016 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Nov 2016</rights><rights>Nature America, Inc., part of Springer Nature. 2016.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c616t-9f77249a1ad48d94e503d9e7c2b67370bbe7ff1469af1473cc1cac08a31936d83</citedby><cites>FETCH-LOGICAL-c616t-9f77249a1ad48d94e503d9e7c2b67370bbe7ff1469af1473cc1cac08a31936d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/cgt.2016.49$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/cgt.2016.49$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27834358$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morano, W F</creatorcontrib><creatorcontrib>Aggarwal, A</creatorcontrib><creatorcontrib>Love, P</creatorcontrib><creatorcontrib>Richard, S D</creatorcontrib><creatorcontrib>Esquivel, J</creatorcontrib><creatorcontrib>Bowne, W B</creatorcontrib><title>Intraperitoneal immunotherapy: historical perspectives and modern therapy</title><title>Cancer gene therapy</title><addtitle>Cancer Gene Ther</addtitle><addtitle>Cancer Gene Ther</addtitle><description>Intraperitoneal immunotherapy represents a novel strategy for the management of peritoneal metastases (PM). Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has remained the gold standard of treatment for patients with PM, yet despite optimal treatment, recurrence rates remain high and long-term survival poor. From Coley’s toxins to immune checkpoint inhibitors, the wide variety of anticancer immunotherapeutic strategies are now garnering attention for control of regional disease of the peritoneal cavity. Early studies with vaccine-based therapies, adoptive cell transfer, immune checkpoint inhibitors, and chimeric T cells with tumor-specific antigen receptors (CAR-T cells) are being performed, showing promise for control of peritoneal spread and induction of lasting anticancer immunity. In addition, catumaxomab, a trifunctional antibody, has been approved for intraperitoneal immunotherapy in Europe for the control of malignant ascites in patients with epithelial cell adhesion molecule positive cancers. We review a brief history of immunotherapy and current modalities under investigation for intraperitoneal use in the treatment of PM.</description><subject>631/250/251</subject><subject>631/67/1059</subject><subject>631/67/322</subject><subject>Animals</subject><subject>Antibodies, Bispecific - therapeutic use</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Ascites</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Cell adhesion molecules</subject><subject>Chemotherapy</subject><subject>Debulking</subject><subject>Epithelial cells</subject><subject>Gene Expression</subject><subject>Gene Therapy</subject><subject>History, 20th Century</subject><subject>History, 21st Century</subject><subject>Humans</subject><subject>Hyperthermic intraperitoneal chemotherapy</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunotherapy</subject><subject>Immunotherapy - history</subject><subject>Lymphocytes T</subject><subject>Metastases</subject><subject>Patients</subject><subject>Peritoneal diseases</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Peritoneal Neoplasms - therapy</subject><subject>Peritoneum</subject><subject>review</subject><issn>0929-1903</issn><issn>1476-5500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqN0s1rFDEUAPAgil2rJ-8yIIigs-Zr8uGtFLULBS96DtlMZjdlJlmTjND_3rfsVttSigQSyPslj5c8hF4TvCSYqU9uU5cUE7Hk-glaEC5F23UYP0ULrKluicbsBL0o5QpjCEr2HJ1QqRhnnVqg1SrWbHc-h5qit2MTpmmOqW497F5_brah1JSDgwigsvOuht--NDb2zZR6n2NztC_Rs8GOxb86rqfo59cvP84v2svv31bnZ5etE0TUVg9SUq4tsT1Xvea-w6zXXjq6FpJJvF57OQyEC21hlsw54qzDyjKimegVO0XvD_fucvo1-1LNFIrz42ijT3MxRHHBNFPkfyjThFLOGNC39-hVmnOEQgwVnEgqMbhHFKTFikNu9U9t7OhNiEOCJ3b71OaMS8w7QgUGtXxAwej9FBx8xhBg_86Bd7cObOGz6rakca4hxXIXfjhAl1Mp2Q9ml8Nk87Uh2OxbxkDLmH3LGK5BvznWNK8n3_-1Nz0C4OMBFAjFjc-3in7gvj9KlMcN</recordid><startdate>20161101</startdate><enddate>20161101</enddate><creator>Morano, W F</creator><creator>Aggarwal, A</creator><creator>Love, P</creator><creator>Richard, S D</creator><creator>Esquivel, J</creator><creator>Bowne, W B</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>7QO</scope><scope>7T5</scope></search><sort><creationdate>20161101</creationdate><title>Intraperitoneal immunotherapy: historical perspectives and modern therapy</title><author>Morano, W F ; Aggarwal, A ; Love, P ; Richard, S D ; Esquivel, J ; Bowne, W B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c616t-9f77249a1ad48d94e503d9e7c2b67370bbe7ff1469af1473cc1cac08a31936d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>631/250/251</topic><topic>631/67/1059</topic><topic>631/67/322</topic><topic>Animals</topic><topic>Antibodies, Bispecific - therapeutic use</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Ascites</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Cell adhesion molecules</topic><topic>Chemotherapy</topic><topic>Debulking</topic><topic>Epithelial cells</topic><topic>Gene Expression</topic><topic>Gene Therapy</topic><topic>History, 20th Century</topic><topic>History, 21st Century</topic><topic>Humans</topic><topic>Hyperthermic intraperitoneal chemotherapy</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunotherapy</topic><topic>Immunotherapy - history</topic><topic>Lymphocytes T</topic><topic>Metastases</topic><topic>Patients</topic><topic>Peritoneal diseases</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Peritoneal Neoplasms - therapy</topic><topic>Peritoneum</topic><topic>review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morano, W F</creatorcontrib><creatorcontrib>Aggarwal, A</creatorcontrib><creatorcontrib>Love, P</creatorcontrib><creatorcontrib>Richard, S D</creatorcontrib><creatorcontrib>Esquivel, J</creatorcontrib><creatorcontrib>Bowne, W B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><jtitle>Cancer gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morano, W F</au><au>Aggarwal, A</au><au>Love, P</au><au>Richard, S D</au><au>Esquivel, J</au><au>Bowne, W B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intraperitoneal immunotherapy: historical perspectives and modern therapy</atitle><jtitle>Cancer gene therapy</jtitle><stitle>Cancer Gene Ther</stitle><addtitle>Cancer Gene Ther</addtitle><date>2016-11-01</date><risdate>2016</risdate><volume>23</volume><issue>11</issue><spage>373</spage><epage>381</epage><pages>373-381</pages><issn>0929-1903</issn><eissn>1476-5500</eissn><abstract>Intraperitoneal immunotherapy represents a novel strategy for the management of peritoneal metastases (PM). Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has remained the gold standard of treatment for patients with PM, yet despite optimal treatment, recurrence rates remain high and long-term survival poor. From Coley’s toxins to immune checkpoint inhibitors, the wide variety of anticancer immunotherapeutic strategies are now garnering attention for control of regional disease of the peritoneal cavity. Early studies with vaccine-based therapies, adoptive cell transfer, immune checkpoint inhibitors, and chimeric T cells with tumor-specific antigen receptors (CAR-T cells) are being performed, showing promise for control of peritoneal spread and induction of lasting anticancer immunity. In addition, catumaxomab, a trifunctional antibody, has been approved for intraperitoneal immunotherapy in Europe for the control of malignant ascites in patients with epithelial cell adhesion molecule positive cancers. We review a brief history of immunotherapy and current modalities under investigation for intraperitoneal use in the treatment of PM.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>27834358</pmid><doi>10.1038/cgt.2016.49</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0929-1903 |
| ispartof | Cancer gene therapy, 2016-11, Vol.23 (11), p.373-381 |
| issn | 0929-1903 1476-5500 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1846393818 |
| source | MEDLINE; SpringerLink Journals |
| subjects | 631/250/251 631/67/1059 631/67/322 Animals Antibodies, Bispecific - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Ascites Biomedical and Life Sciences Biomedicine Cancer Care and treatment Cell adhesion molecules Chemotherapy Debulking Epithelial cells Gene Expression Gene Therapy History, 20th Century History, 21st Century Humans Hyperthermic intraperitoneal chemotherapy Immune checkpoint inhibitors Immunotherapy Immunotherapy - history Lymphocytes T Metastases Patients Peritoneal diseases Peritoneal Neoplasms - secondary Peritoneal Neoplasms - therapy Peritoneum review |
| title | Intraperitoneal immunotherapy: historical perspectives and modern therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T01%3A33%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intraperitoneal%20immunotherapy:%20historical%20perspectives%20and%20modern%20therapy&rft.jtitle=Cancer%20gene%20therapy&rft.au=Morano,%20W%20F&rft.date=2016-11-01&rft.volume=23&rft.issue=11&rft.spage=373&rft.epage=381&rft.pages=373-381&rft.issn=0929-1903&rft.eissn=1476-5500&rft_id=info:doi/10.1038/cgt.2016.49&rft_dat=%3Cgale_proqu%3EA470451260%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1840848468&rft_id=info:pmid/27834358&rft_galeid=A470451260&rfr_iscdi=true |